KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 2

Vascular Endothelial Growth Factor (VEGF) as a Predictor ofActive Acromegaly

Berrin ÇETİNARSLAN
Zeynep CANTÜRK
İlhan TARKUN
Alper Çağrı KARCI
Sayfa
232–239
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The basal GH and IGF-1 levels were significantly higher in the active acromegaly group thanthe controlled acromegaly group (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: To compare vascular endothelial growth factor (VEGF) levels between active and controlled acromegalypatients, to investigate the relationship of VEGF levels with growth hormone (GH) and insulin-like growth factor 1 (IGF1) levels, and to examine the predictive value of VEGF for active disease.
📊
Temel Bulgular & Veri:Methods: Adults (≥18 years) diagnosed with acromegaly were included.
💡
Sonuç & Katkı:The basal GH and IGF-1 levels were significantly higher in the active acromegaly group thanthe controlled acromegaly group (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2010 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: To compare vascular endothelial growth factor (VEGF) levels between active and controlled acromegalypatients, to investigate the relationship of VEGF levels with growth hormone (GH) and insulin-like growth factor 1 (IGF1) levels, and to examine the predictive value of VEGF for active disease. Methods: Adults (≥18 years) diagnosed with acromegaly were included. Blood samples were collected to measure GH,IGF-1, and VEGF levels. Disease activity was determined according to the criteria established in 2010 by the AcromegalyConsensus Group. Results: Seventy-four acromegaly patients (28 with active disease, and 46 with controlled acromegaly, mean age48±14 years) were enrolled. The basal GH and IGF-1 levels were significantly higher in the active acromegaly group thanthe controlled acromegaly group (p

🔖

Bu Makaleye Atıf Yap

ÇETİNARSLAN, B., CANTÜRK, Z., TARKUN, İ., KARCI, A. Ç. (2022). Vascular Endothelial Growth Factor (VEGF) as a Predictor ofActive Acromegaly. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 2, 232–239. https://ajindex.com/articles/508592

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Capatina C, Wass JA. 60 years of neuroendocrinology: acromegaly. J Endocrinol 2015;226:T141–60
  2. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2008;37:101–22, viii
  3. Colao A, Auriemma RS, Pivonello R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 2016;19:210–21
  4. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009;119:3189–202
  5. Găloiu S, Poiană C. Current therapies and mortality in acromegaly. J Med Life 2015;8:411–5
  6. Kanakis GA, Chrisoulidou A, Bargiota A, Efstathiadou ZA, Papanastasiou L, Theodoropoulou A, et al. The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2016;85:681–8
  7. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013;153:13–9
  8. Borg SA, Kerry KE, Royds JA, Battersby RD, Jones TH. Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells. Eur J Endocrinol 2005;152:293–300
  9. Ezzat S. The role of hormones, growth factors and their receptors in pituitary tumorigenesis. Brain Pathol 2001;11:356–70
  10. Lohrer P, Gloddek J, Hopfner U, Losa M, Uhl E, Pagotto U, et al. Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 2001;74:95–105
  11. Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, et al. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol 2006;191:249–61
  12. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95:3141–8
  13. Fuchs S, Gat-Yablonski G, Shtaif B, Lazar L, Phillip M, Lebenthal Y. Vascular endothelial growth factor (VEGF) levels in short, GH treated children: a distinct pattern of VEGF-C in Noonan syndrome. J Endocrinol Invest 2015;38:399–406
  14. Araújo VR, Gastal MO, Wischral A, Figueiredo JR, Gastal EL. In vitro development of bovine secondary follicles in two- and three-dimensional culture systems using vascular endothelial growth factor, insuli